AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01333059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT01333059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT02697175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Live Video-Colposcopy
Description: The colposcopy will be shown in real time on a flat screen
Study NCT02697175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Live Video-Colposcopy
Description: The TV will be shut off during colposcopy
Study NCT03109574 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: BioFlo DuraMax Chronic Hemodialysis Catheter
Study NCT03109574 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Standard of Care Catheter
Study NCT03121547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol 50 mg Oral Tablet
Description: 1 tablet administered
Study NCT03121547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride 100 mg Extended Release Oral Tablet
Description: 1 tablet administered
Study NCT03121547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: calcium tablet
Study NCT01166763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: oral capsules, 10,000 IU per week for 6 months
Study NCT02733367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infacort®
Description: Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
Study NCT01528254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of vildagliptin
Study NCT01528254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin
Description: One tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
Study NCT01528254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
Study NCT01528254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Twice daily (bid) regimen during or after meals at the same time as vildagliptin.
Study NCT03349749 — intervention group
Intervention type: DEVICE
Intervention: LiDCOplus haemodynamic monitor
Description: Patients in study group receive intravenous fluid bolus as part of standard fluid resuscitation. Fluid responsiveness (i.e. improvement in cardiac output) is estimated using both standard clinical parameters and by LiDCOplus haemodynamic monitor (with the clinician initially blinded to the latter) before a final decision about fluid responsiveness is made.
Study NCT03376061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Tranexamic Acid is a medication used to treat or prevent excessive blood loss from major trauma, post partum, surgery, tooth removal, nose bleeds, and heavy menstruation.
Study NCT02308709 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ventilation image-guided radiotherapy
Description: Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
Study NCT03669185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentalong
Description: Pentalong, 2 x daily 1 tablet, intake max. 133 days
Study NCT03669185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos, 2 x daily 1 tablet, intake max. 133 days
Study NCT03172975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albendazole
Description: Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
Study NCT03172975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Necator americanus Larval Inoculum
Description: 50 infectious Necator americanus larvae applied via dermal application (challenge infection).
Study NCT03852537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone will be administered based on CRP-guided protocol outlined under 'Biomarker-adjusted steroid dosing'.
Study NCT03852537 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care as determined by the patients treatment team.
Study NCT00422500 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Surveys about symptoms, mood, and quality of life.
Study NCT00422500 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone Interactive System
Description: Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
Study NCT00356434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kendall A-V foot impulse pump, model 6060
Description: Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
Study NCT00356434 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kendall sequential compression device, model 9525
Description: Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
Study NCT01568983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
Study NCT01568983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mana-juice
Description: 500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
Study NCT01568983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Optijuice
Description: 500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
Study NCT00422500 — intervention group
Intervention type: OTHER
Intervention: Blood Samples
Description: For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
Study NCT03172975 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Necator americanus Larval Inoculum
Description: 50 infectious Necator americanus larvae applied via dermal application (challenge infection).
Study NCT03116191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SK-1404
Description: 4 weeks of repeated administration of SK-1404 to the patients of nocturia
Study NCT05466591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pre-hospital rule-out strategy
Description: Point-of-care troponin measurement for pre-hospital rule-out of acute coronary syndrome
Study NCT03870646 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hypertonic saline of NaCl (7%) in combination with hyaluronic acid
Description: Critical adult tracheostomized patients will receive, in the intervention arm, nebulized Hypertonic saline of NaCl (7%) in combination with hyaluronic acid 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with hypersaline in order to avoid bronchospasm.
Study NCT03870646 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline of NaCl (0,9%)
Description: Critical adult tracheostomized patients will receive, in the control arm, nebulized isotonic saline of NaCl (0,9%) 5ml twice daily for 10 days from the day of the tracheotomy or until decannulation or discharge from the ICU if it happens before. The treatment will be applied through a jet nebulizer located in the inspiratory branch in patients under mechanical ventilation and in the sole tubulant of patients under T-piece oxygen regimen. Salbutamol 100 micrograms / dose, suspension for inhalation in pressure pack: 2 inhalations through the tracheostomy cannula 10 minutes before the application of the nebulization with isotonic saline in order to avoid bronchospasm.
Study NCT04501419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided breast biopsy
Description: During this study, women with undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.
Study NCT04501419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided breast biopsy training program
Description: This program, developed by experts in Nigeria and the United States of America, certifies that they have the skills required to safely perform these biopsies on patients
Study NCT03928106 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pharmacists' recommendation
Description: For patients in the intervention group, upon identification of drug discrepancies, pharmacist responsible for enrollment will be intervened by contacting the responsible clinician using a structured written consult form. The number of accepted recommendations by the clinicians will be documented and recorded. When the researcher suggests resolving an identified discrepancy and the responsible clinicians accept the suggestion will be called an accepted recommendation (just an acceptance without any correction), if the accepted suggestion is implemented then this will be called implemented recommendation.
Study NCT00694265 — intervention group
Intervention type: PROCEDURE
Intervention: Decompression
Description: Surgical decompression of the median nerve
Study NCT00694265 — intervention group
Intervention type: PROCEDURE
Intervention: Conservative treatment
Description: Conservative treatment typically consisted of splinting and corticosteroid injections
Study NCT02908841 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Surgicel Snow
Study NCT02908841 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Study NCT00696644 — intervention group
Intervention type: DRUG
Intervention: Teriparatide
Description: 20 mcg daily subcutaneous for 18 months.
Study NCT01654406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser and pulsed dye laser
Description: Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
Study NCT01654406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed dye laser
Description: Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
Study NCT03560479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha1H, 7.4 mg/mL
Description: Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
Study NCT03560479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
Study NCT03560479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha1H, 37 mg/mL
Description: Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
Study NCT03560479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha1H, 74 mg/mL
Description: Intravesical instillations on 6 occasions during 22 days (Days 1, 3, 5, 8, 15 and 22)
Study NCT02827331 — intervention group
Intervention type: OTHER
Intervention: Exposition to hypnotics or anxiolytics benzodiazepines
Description: Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Benzodiazepine derivatives (N05BA)~* Benzodiazepine derivatives (N05CD)~* Benzodiazepine related drugs (N05CF)
Study NCT02827331 — intervention group
Intervention type: OTHER
Intervention: Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics
Description: Exposition to at least one drug belonging to the following classes during the last 12 months before index date :~* Antipsychotics (N05A)~* Antiepileptics with the exception of clonazepam (N03)~* Drugs used for alcohol dependance (N07BB)~* Drugs used for opioids dependance (N07BC)
Study NCT02827331 — intervention group
Intervention type: OTHER
Intervention: Medical consultation without prescription
Description: Medical consultation without prescription of any drugs of interest
Study NCT03601130 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HydroxyColl Bone Graft Substitute
Description: The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) with the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
Study NCT03601130 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)
Description: The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
Study NCT03601130 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care)
Description: The intervention involves the use of Open Wedge High Tibial Osteotomy with DePuy Synthes TomoFix Medial High Tibial Plate (MHT) fixation (Standard of Care) without the HydroxyColl bone graft substitute i.e. bone graft substitute vs. no bone graft substitute.
Study NCT00275574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture
Study NCT02667067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simplify Disc
Description: Simplify Disc at one level in the cervical spine.
Study NCT02667067 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Anterior Cervical Discectomy & Fusion
Description: This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®\|C Disc trial.
Study NCT01015937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Turmeric extract
Description: turmeric 500 mg TID for 45 days
Study NCT02046109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair
Study NCT02046109 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Replace
Study NCT01839773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Study NCT01839773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LP0113 aerosol spray
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LP0113 aerosol spray
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosol spray vehicle
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 aerosol foam
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam
Study NCT01015937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
Description: maximum dosage as patient tolerated for 45 days
Study NCT04368351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: SivoMixx (200 billion)
Description: Composition of SivoMixx: Streptococcus thermophilus DSM322245, Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961 (NB: DSM n°... : bacterial strain identification code)
Study NCT04368351 — intervention group
Intervention type: DRUG
Intervention: Azithromycin
Description: dose: 500mg 1 cp / day (alternatively lopinavir/ritonavir cps 200/50 mg, 2 cps x 2 / day or darunavir 800 mg 1 cp / day + ritonavir 100 mg 1 cp / day or darunavir/cobicistat 800/150 mg 1 cp / day)
Study NCT04368351 — intervention group
Intervention type: DRUG
Intervention: hydroxychloroquine
Description: dose: 200 mg, 1 cp x 2 / day
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betamethasone dipropionate aerosol spray
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone dipropionate aerosol spray
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcipotriol aerosol spray
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol aerosol spray
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daivobet® gel
Study NCT02416258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daivobet® gel
Study NCT01683955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Topical tranexamic acid (2g/100mL 0.9% saline)
Study NCT01683955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100mL 0.9% sterile saline
Study NCT00293644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclectin®
Description: Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
Study NCT04039607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Participants will receive ipilimumab as IV infusion.
Study NCT04039607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Participants will receive sorafenib as oral tablets.
Study NCT00293644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclectin®
Description: Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
Study NCT01822405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pentoxifylline with tocopherol
Description: Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
Study NCT01822405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy
Description: pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.~Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment.
Study NCT01133301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg/d Naltrexone will be administrated during three weeks.
Study NCT01133301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone
Description: 50 mg/d Naltrexone will be administrated during three weeks.
Study NCT01133301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: During 3 weeks of the study, Placebo will be administrated (daily)
Study NCT01133301 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During 3 weeks of the study, Placebo will be administrated (daily)
Study NCT01124136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation + Medication Management (Standard of Care)
Description: In addition to medication management, adding investigational implanted neurostimulator to heart
Study NCT02252406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24
Study NCT02252406 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets daily for 24 weeks.
Study NCT01124136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (Control)
Description: Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.
Study NCT01124136 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care (Control)
Description: Standard of Care Therapy consists of medication management only to support heart for rhythm, anticoagulation, and rate, and comorbid symptoms, i.e. diuretics, lipid lowering.